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Abstract 
Background: Coenzyme Q10 (CoQ10 or ubiquinone) deficiency can be due either to mutations in genes involved in 
CoQ10 biosynthesis pathway, or to mutations in genes unrelated to CoQ10 biosynthesis. CoQ10 defect is the only oxida‑
tive phosphorylation disorder that can be clinically improved after oral CoQ10 supplementation. Thus, early diagnosis, 
first evoked by mitochondrial respiratory chain (MRC) spectrophotometric analysis, then confirmed by direct meas‑
urement of CoQ10 levels, is of critical importance to prevent irreversible damage in organs such as the kidney and the 
central nervous system. It is widely reported that CoQ10 deficient patients present decreased quinone‑dependent 
activities (segments I + III or G3P + III and II + III) while MRC activities of complexes I, II, III, IV and V are normal. We 
previously suggested that CoQ10 defect may be associated with a deficiency of CoQ10‑independent MRC complexes. 
The aim of this study was to verify this hypothesis in order to improve the diagnosis of this disease.
Results: To determine whether CoQ10 defect could be associated with MRC deficiency, we quantified CoQ10 by 
LC‑MSMS in a cohort of 18 patients presenting CoQ10‑dependent deficiency associated with MRC defect. We found 
decreased levels of CoQ10 in eight patients out of 18 (45 %), thus confirming CoQ10 disease.
Conclusions: Our study shows that CoQ10 defect can be associated with MRC deficiency. This could be of major 
importance in clinical practice for the diagnosis of a disease that can be improved by CoQ10 supplementation.
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Background
Coenzyme Q10 (CoQ10 or ubiquinone) is a lipid-soluble 
component of the mitochondrial inner membrane that 
plays a central role in mitochondrial respiratory chain 
(MRC) function, as electrons carrier from complexes I 
and II to complex III, thus participating in ATP produc-
tion [1].
CoQ10 deficiency encompasses several clinical phe-
notypes such as encephalomyopathy, severe infantile 
multisystemic disease, cerebellar ataxia, isolated myopa-
thy or nephrotic syndrome [2]. CoQ10 deficiency can be 
primary, due to mutations in genes involved in CoQ10 
biosynthesis or secondary, due to mutations in genes 
unrelated to CoQ10 biosynthesis [3]. Secondary CoQ10 
deficiency has been described in patients with mito-
chondrial DNA (mtDNA) mutations or deletions, with 
mtDNA depletion syndrome (MDS) [4–6] and in patients 
with mutations in APTX [7], ETFDH [8, 9], BRAF [10], 
ACADVL or NPC genes [11]. CoQ10 defect is the only 
oxidative phosphorylation (OXPHOS) disorder that can 
be clinically improved after oral CoQ10 supplementation 
with limitation of neurological and renal manifestations, 
amelioration of muscular symptoms and attenuation of 
histological alterations. Early treatment is crucial to pre-
vent irreversible damage in organs such as the kidney and 
the central nervous system [12–14]. Reduced activities 
of CoQ10-dependent enzymes by spectrophotometric 
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analysis (segments I + III or G3P + III and II + III) are 
evocative of CoQ10 deficiency but direct measurement of 
CoQ10 levels is the most reliable test for diagnosis [15]. It 
is widely reported in the literature that, in patients with 
CoQ10 deficiency, enzymatic activities of MRC complexes 
I, II, III, IV, V are normal [16]. In a previous report, we 
described an 11-year-old boy presenting with a propionic 
acidemia who succumbed to acute heart failure in the 
absence of decompensation of his metabolic condition. 
Spectrophotometric analysis in liver identified CoQ10-
dependent activities deficiency that was associated with 
MRC enzymatic defect. Secondary CoQ10 deficiency 
was likely involved in the development of heart compli-
cations in this child and we hypothesized that a CoQ10-
defect may be associated with MRC deficiency [17]. The 
aim of this study was to verify this hypothesis in order to 
improve the diagnosis of this disease.
Over a 6-year period, we analyzed by spectropho-
tometry 700 tissue samples from 495 patients in whom 
a mitochondrial disease was suspected. Isolated CoQ10-
dependent activity deficiency led to identification of 
CoQ10 disease in eight cases. Eighteen patients presented 
CoQ10-dependent enzymatic deficiency associated with 
MRC defect by spectrophotometry in muscle or in fibro-
blasts. In order to validate our original observation and to 
establish if CoQ10 quantitative defect may be associated 
with multiple MRC enzymatic deficiency, we measured 
CoQ10 in this group of 18 patients. We found decreased 
CoQ10 levels by liquid chromatography coupled with tan-
dem mass spectrometry detection (LC-MSMS) in eight 
patients out of 18 (45 %), thus confirming CoQ10 disease 
and its association with MRC enzymatic deficiency. Fur-
thermore, CoQ10 disease cannot be ruled out in all other 
patients insofar as the quantitative assay could not always 
be performed in the affected tissue.
Results
Description of patients involved in the study
We studied 18 patients, including 10 males and eight 
females, ranging in age from day 1 to 76  years. Clinical 
presentations were very heterogeneous (Table 1). The age 
at onset of the disease was highly variable, ranging from 
(i) neonatal forms (seven cases with severe phenotypes), 
(ii) onset before 1 year of age (four cases with either Leigh 
syndrome or epileptic encephalopathy), (iii) childhood-
onset (four cases including two myopathic forms and two 
complex phenotypes) to (iv) adult-onset (three cases with 
two myopathic presentations and one cerebellar ataxia). 
The 18 patients were divided into two different groups 
according to molecular results.
The first group included 10 patients with identified 
mutations in responsible genes (Table 1). Patient P01 pre-
sented a severe neonatal multisystemic disease secondary 
to a homozygous missense mutation in the CoQ2 gene 
[18]. Spectrophotometric analysis in fibroblasts revealed 
a CoQ10-dependent activities defect (segments II  +  III 
and G3P +  III reduction) associated with a complex IV 
deficiency (Table 2). Six patients (P02–P07) presented a 
mitochondrial disease or dysfunction secondary either to 
mtDNA abnormalities (P02 and P03) or to mutations in 
nuclear genes (P04–P07). Patient P02 had a large hetero-
plasmic mtDNA deletion responsible for Kearns–Sayre 
syndrome and patient P03 presented with a severe neo-
natal polyvisceral failure secondary to a heteroplasmic 
mtDNA mutation in the MT-CYB gene. Patients P04 
and P05 presented with sensory ataxia neuropathy dys-
arthria and ophthalmoplegia (SANDO) phenotype asso-
ciated with recessive mutations in POLG. Patient P06 
had a neonatal encephalopathy with lactic acidosis and 
mild methylmalonic aciduria linked to mutations in the 
SUCLG1 gene. P07 had a diagnosis of multiple acyl-CoA 
dehydrogenation deficiency (MADD) with ETFDH muta-
tion. The last three patients in the first group presented 
malignant migrating partial seizures with mutations in 
TBC1D24 (P08), CDG syndrome type Iq with SRD5A3-
CDG mutations (P09) and 1p36 deletion syndrome (P10). 
Patients P02–P10 had a CoQ10-dependent activities defi-
ciency (segments I + III or G3P + III and II + III reduc-
tion) associated with a multiple MRC defect in muscle or 
in fibroblasts (Table 2).
The second group included eight patients suspected of 
CoQ10 deficiency with an absence of molecular diagno-
sis. Except for individual P11, who developed cerebellar 
ataxia during adulthood, all patients had an early-onset 
disease ranging from neonatal period to childhood. 
They presented severe neurological symptoms including 
two Leigh syndromes (P12 and P16) and one child had 
an unexplained severe respiratory failure at birth (P17). 
In the second group, all patients presented a CoQ10-
dependent enzymatic deficiency associated with MRC 
defect in muscle or in fibroblasts (Table 2).
Confirmation of CoQ10disease in eight patients by CoQ10 
quantification
Quantitative analysis of CoQ10 in muscle or fibroblasts 
showed that eight patients presented CoQ10 content 
below normal values (Table  2). CoQ10 defect was found 
in five patients out of 10 in the first group and in three 
patients out of eight in the second group. CoQ10-defi-
cient individuals were six males and two females, rang-
ing in age from day 1 to 76 years. The age of onset was 
highly variable, ranging from neonatal forms to diseases 
appearing after 25 years of age, although six patients had 
childhood onset. One patient (P01) presented a polyvis-
ceral failure at birth and all the others had neurological 
symptoms either isolated or combined with muscular 
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and/or other signs. In the first group, the very low CoQ10 
level observed in the fibroblasts of patient P01 confirmed 
the primary CoQ10 defect associated with the c.437G > A 
homozygous missense mutation (p.Ser146Asn) in the 
CoQ2 gene, involved in CoQ10 biosynthesis [18]. In the 
four other patients in the same group, CoQ10 defect was 
clearly secondary because the responsible genes were 
unrelated to CoQ10 biosynthesis. Three patients had a 
mitochondrial disease linked to a large mtDNA dele-
tion (patient P02) or to mutations in POLG (patient 
P04) or SUCLG1 (patient P06). Patient P08 alone did 
not have a mitochondrial disease, her encephalopa-
thy with refractory malignant migrating partial seizures 
being linked to mutations in the TBC1D24 gene. In the 
second group, low CoQ10 levels were found in three 
patients with no molecular diagnosis. Two patients were 
strongly suspected of having a mitochondrial disease: 
patient P11, who had a cerebellar ataxia with 20–30  % 
of COX-negative fibers and multiple mtDNA deletions 
in muscle, and patient P16 who presented with a Leigh 
syndrome. The last patient (P15) had an encephalopa-
thy with intellectual disability but no histological sign of 
mitochondrial myopathy.
Discussion
While primary CoQ10 defects are rare, secondary defects 
have been observed in various pathologies. In a pre-
vious work, we suspected for the first time a second-
ary CoQ10 defect in a child with propionic acidemia, 
who succumbed to acute heart failure in the absence of 
decompensation of his metabolic condition [17]. CoQ10 
deficiency was not evoked at the outset because CoQ10-
dependent activities deficiency was associated with mul-
tiple MRC deficiency in the liver of the patient and it had 
been widely reported that enzymatic activities of MRC 
complexes are normal in CoQ10 disease [16]. However, it 
Table 2 Biochemical analysis of patient fibroblasts and muscle biopsies
Respiratory chain enzyme activities were measured spectrophotometrically. Results are expressed as absolute values for controls or patients (in nanomoles of 
substrate per minute per milligram of protein). CoQ10 quantity was measured by LC-MSMS. Results are expressed as absolute values for controls or patients (in 
picomoles per milligram of protein). Abnormal values are shown in italics
OXPHOS oxidative phosphorylation; LC-MSMS liquid chromatography coupled with tandem mass spectrometry detection
OXPHOS activities 
(spectrophotometry)










P01 11.2 27.7 89.7 29.2 33.5 2.3 7.5 156.2 P01 1.4
P03 11.5 18.5 21.3 177.7 34.1 4.1 12.5 106.7 P03 65.4
P04 7.5 18.6 40.2 108.2 30.5 4.7 8.6 95.0 P04 9.7
P06 11.6 20.6 47.9 78.1 37.6 5.5 10.8 116.6 P06 5.9
P09 12.0 13.4 53.4 57.0 15.8 4.1 8.9 80.9 P09 62.0
P10 13.5 22.9 54.4 65.0 28.3 5.4 12.0 148.2 P10 55.9
P12 10.9 17.6 76.6 173.3 25.0 4.4 10.1 102.5 P12 62.1
P16 11.2 20.7 57.4 134.9 38.3 6.1 14.5 124.0 P16 5.7
P17 12.9 20.0 61.5 181.7 29.3 5.6 14.7 130.3 P17 58.1








P02 6.7 21.5 130.4 56.9 32.5 7.4 10.8 113.4 P02 16.0
P05 5.7 21.2 28.9 59.4 12.7 10.9 15.2 122.2 P05 35.5
P07 4.2 28.6 108.8 170.4 50.0 10.5 16.7 272.4 P07 25.9
P08 10.9 14.1 102.5 92.8 63.3 10.8 17.0 116.5 P08 5.7
P11 25.7 29.7 157.6 80.2 45.0 13.6 19.6 109.9 P11 6.2
P13 7.6 28.9 112.7 212.7 58.4 9.4 13.4 192.6 P13 22.4
P14 15.5 26.6 31.6 154.5 32.8 13.7 13.2 100.5 P14 22.2
P15 16.2 20.0 92.3 191.7 39.8 11.9 17.5 86.1 P15 7.1
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is likely that a secondary CoQ10 defect was involved in the 
development of heart complications leading to the child’s 
death and that oral CoQ10 supplementation would have 
been able to prevent cardiac failure if results had been 
obtained before acute clinical aggravation. This hypoth-
esis is supported by a recent study, which describes a 
successful reversal of propionic acidemia-associated car-
diomyopathy after treatment [19]. The child in this case 
presented with myocardial CoQ10 quantitative defect 
associated with signs of mitochondrial dysfunction such 
as enlarged mitochondria with atypical cristae and low 
MRC complex IV activity [19]. Several studies performed 
on cellular models of CoQ10 defect suggested a possible 
association with mitochondrial dysfunction: PDSS2 and 
COQ9 mutant fibroblasts presented a markedly reduced 
ATP synthesis and COQ2 mutant fibroblasts presented 
a partial defect in ATP synthesis, as well as significantly 
increased ROS production and oxidation of lipids and 
proteins [20, 21]. In 2013, Duberley and colleagues estab-
lished the first pharmacologically-induced CoQ10 defi-
cient cellular model in neuroblastoma-derived SH-SY5Y 
cells by using para-aminobenzoic acid (PABA). They 
showed that, after PABA treatment, SH-SY5Y cells pre-
sented a progressive decrease in the activities of CoQ10-
dependent II + III segment but also a deficiency in MRC 
complexes I and IV. They also reported a concomitant 
decrease in the level of total cellular ATP with an increase 
of mitochondrial oxidative stress [22]. Lastly, deficiency 
of complexes I, II, III and/or IV has also been previously 
reported in association with CoQ10 defect in the patient’s 
fibroblasts, muscle or kidney [8, 11, 18, 23].
Today, in most diagnostic laboratories, a spectropho-
tometric deficiency in one or several MRC enzymes 
associated with a decrease in CoQ10-dependent activi-
ties is not considered to be a sign of a CoQ10 disease, 
leading to a possible under-estimation of the frequency 
of this disorder. With the aim of achieving a better diag-
nostic approach, we quantified CoQ10 by LC-MSMS in 
18 patients presenting a CoQ10-dependent enzymatic 
deficiency associated with a MRC defect by spectro-
photometry. CoQ10 quantitative analysis in muscle or in 
fibroblast cells confirmed CoQ10 disease in eight patients 
(45 %). These data show that a primary CoQ10 defect can 
be associated with MRC enzymatic deficiency because 
patient P01, who carried a deleterious homozygous muta-
tion (c.437G  >  A; p.Ser146Asn) in the CoQ2 gene, also 
presented a complex IV deficiency in muscle. Our data 
also confirm that a secondary CoQ10 defect can be asso-
ciated with mitochondrial disease. Indeed, three other 
patients with a low CoQ10 level presented a respiratory 
chain deficiency linked to mtDNA deletion (patient P02) 
or to mutations in POLG and SUCLG1 genes (patients 
P04 and P06). Secondary CoQ10 defect has already been 
reported in patients with mitochondrial diseases or 
dysfunctions including Kearns–Sayre syndrome [24], 
mtDNA depletion and PEO [5] or mutations in ETFDH 
coding for electrontransferring-flavoprotein dehydroge-
nase and causing MADD [8, 9]. Secondary CoQ10 defect 
has also been described in non-mitochondrial disorders 
linked to genes such as APTX coding for aprataxin and 
causing ataxia occulomotor-apraxia [7], BRAF coding for 
serine/threonine-protein kinase B-Raf and causing car-
diofaciocutaneous syndrome [10], ACADVL causing very 
long-chain Acyl-CoA dehydrogenase deficiency or NPC 
causing Niemann-Pick-type C disease [11]. Here, we 
report for the first time a secondary CoQ10 defect asso-
ciated with mutations in the TBC1D24 gene, leading to 
malignant migrating partial seizures (Patient P08). The 
mechanisms linking CoQ10 defect and decreased activ-
ity of MRC complexes are unknown. Studies in patients 
with metabolic diseases showed an increase in oxidative 
stress-markers and a decrease in antioxidant defences 
[25]. More specifically, ubiquinol depletion in patient tis-
sues may lead to increased reactive oxygen species activ-
ity [26] and, since all enzymes of the MRC are susceptible 
to free radical induced oxidative damage [27], we can 
hypothesize that CoQ10-independent MRC dysfunction 
may result from a high level of mitochondrial oxidative 
stress creating an imbalance with the CoQ10 antioxidant 
capacity, as previously evoked [25]. In parallel, a possi-
ble reason for a secondary CoQ10 defect resulting from 
a primary MRC deficiency is that the enzymes involved 
in CoQ10 biosynthesis are found in a supercomplex in 
the inner mitochondrial membrane [28]. We hypothesize 
that the increased oxidative stress resulting from a pri-
mary MRC deficiency may inhibit these enzymes result-
ing in a secondary CoQ10 defect.
Conclusions
In conclusion, our work highlights the probability that, 
based on spectrophotometric analysis, the frequency 
of CoQ10 disease is underestimated in routine clinical 
practice. Several studies, which performed a systematic 
CoQ10 quantification on muscle biopsies from pediatric 
and adult populations presenting a wide range of clinical 
phenotypes, also reported an underestimation of CoQ10 
defects and proposed a systematic evaluation of CoQ10 
content in all muscle biopsies [5, 29, 30]. However, first-
line CoQ10 quantification seems difficult to set up as a 
routine analysis in all diagnosis laboratories. Based on 
our observations, we suggest that CoQ10 quantification 
be performed in all tissues presenting a spectrophoto-
metric deficiency of CoQ10-dependent enzymes, associ-
ated or not with MRC defect, regardless of the patient’s 
age, clinical presentation or molecular diagnosis. This 
could prove of great value in clinical practice for the 
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All patients were explored in the Reference Centre for 
Mitochondrial Disease (CHU of Nice, France). Selection 
of the 18 patients was based on the following inclusion 
criteria: (1) availability of a muscle sample or fibroblast 
culture and (2) spectrophotometric deficiency of CoQ10-
dependent activities (reduction of segments I  +  III or 
G3P +  III and II +  III) associated with MRC defect in 
muscle or in fibroblasts. The following data were system-
atically collected: sex, age at biopsy, age of onset, hered-
ity, familial history, clinical presentation, brain MRI, 
metabolic screening, mitochondrial enzymatic studies, 
histological and molecular analyses. The age of onset 
of clinical symptoms ranged from neonatal period to 
45 years of age. Blood and tissue samples were obtained 
after adult patients and parents of affected children had 
given informed consent.
Patients were divided into two groups (Table  1), 
according to the results of molecular analysis: (1) indi-
viduals with a molecular diagnosis, carrying mutations in 
mtDNA or in nuclear genes and, (2) individuals with no 
molecular diagnosis.
Cell culture
Primary fibroblast cultures were obtained from patient 
skin punches, using standard procedures, in RPMI 
medium supplemented with 10  % Fetal Bovine Serum, 
45  μg/ml uridine and 275  μg/ml sodium pyruvate. Cul-
tures were incubated at 37 ℃ with 5 % CO2.
OXPHOS spectrophotometric measurements
Enzymatic spectrophotometric measurements of the 
OXPHOS respiratory chain complexes and citrate syn-
thase were performed at 37 ℃ on muscle crude homoge-
nates or fibroblasts according to standard procedures 
[31]. Proteins were measured according to Bradford 
microassay [32] and results were expressed as nmole/
min/mg of proteins.
Coenzyme Q10 quantification
Total coenzyme Q10 was extracted from tissues and ana-
lyzed by reverse phase liquid chromatography separation 
(column C18 symmetry 150 × 2.1 mm, 3.5 µm, Waters, 
France) as previously described [33]. Detection and 
quantification were done by mass spectrometry using an 
API 3000 tandem mass spectrometer (ABSciex, France) 
equipped with an APCI source. CoQ10 and CoQ9 were 
analyzed in the positive mode using the following m/z 
864 →  197 and 796 →  197 transitions. CoQ9 was used 
as internal standard for quantification. External calibra-
tion was performed using CoQ10 solutions. A stock solu-
tion was prepared by dissolving 10 mg of CoQ10 in 4 ml 
of methanol/chloroform (98:2 v/v). This solution was sta-
ble for 3 months at −80 °C. The working solutions were 
prepared daily by diluting the stock solution into metha-
nol to provide a range of 0.05–1 µmol/L. The intra-assay 
and inter-assay CV’s were, respectively, 5.7 and 6.3 % for 
a CoQ10 concentration of 0.25 µmol/L.
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